PART I A. Overview Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patients tumor neoantigens. Importantly, our oncolytic immunotherapy product candidates are off-the-shelf personalized immunotherapies....
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001493152-26-011616 | EDGAR | 99K words |
| 2025-03-28 | 2024-12-31 | 0001641172-25-001184 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001493152-24-011946 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001193125-23-083829 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001493152-25-020874 | EDGAR | 29K words |
| 2025-08-07 | 2025-06-30 | 0001641172-25-022583 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001641172-25-008838 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045790 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032145 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018436 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041151 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-027998 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016832 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001493152-26-011649 | EDGAR | 23K words |
| 2026-02-02 | 0001493152-26-004755 | EDGAR | — |
| 2026-01-08 | 0001493152-26-000989 | EDGAR | — |
| 2026-01-05 | 0001493152-26-000270 | EDGAR | — |
| 2026-01-02 | 0001493152-26-000115 | EDGAR | — |
| 2025-09-03 | 0001641172-25-026390 | EDGAR | — |
| 2025-03-25 | 0001641172-25-000642 | EDGAR | — |
| 2025-03-25 | 0001641172-25-000528 | EDGAR | — |
| 2025-02-03 | 0001493152-25-004554 | EDGAR | — |
| 2024-11-08 | 0001493152-24-044258 | EDGAR | — |
63 total filings indexed. 40 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001231457 |
| Ticker | GNLX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.genelux.com |
| Listed | 2023-01-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report